Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Distribution of PF-06687234 in Moderate to Severe UC and Crohn's Disease
NCT03414788Phase 1Withdrawn
- Sponsor
- Pfizer
- Start
- Dec 2020
- Primary completion
- Feb 2022
- Modality
- Antibody Conjugates, Cytokines & Interferons, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of f8il10 in ulcerative colitis (UC) and Crohn's disease, sponsored by Pfizer. Primary endpoints: Percent injected radioactivity dose per kilogram (% ID/kg) in the colon (inflamed and non inflamed) and plasma at 24 hours and Standardized uptake value (SUV) in the colon (inflamed and non inflamed) at 24 hours. Planned start Dec 2020; status: withdrawn.
02
Drugs
f8il10
03
Conditions
ulcerative colitis (UC)Crohn's disease
Beyond the preview
Go deeper on NCT03414788.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03414788.